Pyxis Oncology (PYXS) Common Equity (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Common Equity data on file, last reported at $53.4 million in Q4 2025.

• On a quarterly basis, Common Equity fell 55.77% year-over-year to $53.4 million in Q4 2025; TTM through Dec 2025 was $53.4 million, a 55.77% decrease from a year earlier, with the FY2025 full-year figure at $53.4 million, down 55.77% from the prior year.
• Common Equity for Q4 2025 stood at $53.4 million, down from $68.8 million in the prior quarter.
• Over the last five years, Common Equity for PYXS reached as high as $261.3 million in Q4 2021 and fell as low as -$71.4 million in Q3 2021.
• Historically, Common Equity has averaged $119.0 million across 5 years, with a median of $141.6 million in 2023.
• On a YoY basis, Common Equity climbed as much as 1770.27% in 2021 and fell as far as 544.35% in 2021.
• Year by year, Common Equity stood at $261.3 million in 2021, then slumped by 38.46% to $160.8 million in 2022, then dropped by 21.84% to $125.7 million in 2023, then fell by 3.94% to $120.8 million in 2024, then plunged by 55.77% to $53.4 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $53.4 million in Q4 2025, $68.8 million in Q3 2025, and $87.6 million in Q2 2025.